MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

ClinicalTrials.gov ID: NCT05655312

Public ClinicalTrials.gov record NCT05655312. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/IIa, First-In-Human, Multi-Center, Monotherapy and Combination-Therapy With Nivolumab, Dose-Finding and Dose-Expansion Study of [212Pb]VMT01 Melanocortin-1 Receptor-Targeted, Image-Guided Alpha-Particle Therapy in Subjects With Previously Treated Unresectable or Metastatic Melanoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with nivolumab in subjects with unresectable and metastatic melanoma.

Study identification

NCT ID: NCT05655312
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Perspective Therapeutics; Industry
Enrollment: 300 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 90 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 31, 2023
Primary completion: Dec 30, 2027
Completion: Dec 30, 2029
Last update posted: Jun 9, 2026

2023 – 2029

United States locations

U.S. sites: 13
U.S. states: 9
U.S. cities: 12

Facility	City	State	ZIP	Site status
University of California Irvine	Orange	California	92868	Recruiting
Mayo Clinic	Jacksonville	Florida	32224	Recruiting
University of Miami	Miami	Florida	33136	Recruiting
Sarasota Memorial Hospital	Sarasota	Florida	34239	Recruiting
University of Iowa	Iowa City	Iowa	52242	Recruiting
University of Kentucky	Lexington	Kentucky	40536	Recruiting
Mayo Clinic Rochester	Rochester	Minnesota	55905	Recruiting
Saint Louis University Hospital	St Louis	Missouri	63110	Recruiting
Washington University of St. Louis	St Louis	Missouri	63110	Recruiting
Nebraska Cancer Specialists	Omaha	Nebraska	68130	Recruiting
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	Recruiting
UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania	15232	Recruiting
University of Wisconsin Carbone Cancer Center	Madison	Wisconsin	53792	Active, not recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05655312, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 9, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05655312 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →